[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563013":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":31,"locations":38,"responsibleParty":55,"collaborators":30,"id":59,"slug":30,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":30,"enrollmentInfo":67,"targetDuration":30,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":79,"whyStopped":30,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"combination therapy","EXPERIMENTAL","combination of 5-day remdesivir and 10-day Nirmatrelvir\u002FRitonavir",[13,14],"Drug: combination therapy","Drug: SOC",{"label":16,"type":17,"description":18,"interventionNames":19},"SOC","ACTIVE_COMPARATOR","standard of care",[14],[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","A combination of 5-day remdesivir and 10-day Nirmatrelvir\u002FRitonavir",[9],[26],"remdesivir and Nirmatrelvir\u002FRitonavir",{"type":22,"name":16,"description":28,"armGroupLabels":29,"otherNames":30},"Standard of care",[16,9],null,[32],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Jann-Tay Wang, M. D., Ph.D.","CONTACT","+886-2-2312-3456","263517","wangjt1124@ntuh.gov.tw",[39],{"facility":5,"status":30,"city":40,"state":30,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Taipei","100225","Taiwan",{"type":44,"coordinates":45},"Point",[46,47],121.52639,25.05306,{"lat":47,"lon":46},[50],{"name":51,"role":34,"phone":52,"phoneExt":53,"email":54},"Fu-Chang Tsai, Professor","+886-2312-3456","288576","fctsai@ntu.edu.tw",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","National Taiwan University Clinical Trial Center","Clinical professor,","100563013",false,"NCT06610643","Extended Remdesivir Infusion Combined With Nirmatrelvir\u002FRitonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients","SARS-CoV-2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Receive B-cell depletion therapy or bendamustine within 6months\n* Laboratory confirmed SARS-CoV-2 infection\n* Symptoms onset within 72 hours\n* NIAID ordinal score 0-5 upon enrollment\n\nExclusion Criteria:\n\n* Prior use of any anti-SARS-CoV-2 agents within 2 weeks. Remdesivir or NMV\u002Fr initiated within 24 hours is acceptable\n* Life expectancy \\< 1 month\n* Previous adverse effect related to remdesivir or NMV\u002Fr\n* Concurrent use medicine with drug-drug interaction with NMV\u002Fr\n* Patients receiving intubation and mechanical ventilation\n* eGFR \\< 30\n* Child pugh score Class C\n* Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol.","ALL","18 Years",{"count":68,"type":69},40,"ESTIMATED","INTERVENTIONAL",[72],"NA","To evaluate the safety and efficacy of extended remdesivir infusion, targeting on immunocompromised individuals who had positive SARS-CoV-2 PCR despite an oral antiviral agent prescription.",[75,63,76],"COVID-19","Immunocompromised",[78],"Extended RDV infusion combination therapy for SARS-CoV-2 infection in immunocompromised patients","NOT_YET_RECRUITING","2024-09-24",{"date":82,"type":83},"2024-09-25","ACTUAL",{"date":85,"type":69},"2024-09-21",{"date":87,"type":69},"2026-12-31",{"name":5,"class":6},1]